References

American Public Health Association. Support for women's inclusion in HIV-related clinical research. 2022. https://tinyurl.com/3md6cnt8 (accessed 25 February 2025)

Diversity and equity in HIV cure research: a research briefing. 2024. https://tinyurl.com/mryus4dh (accessed 25 February 2025)

Clark LT, Watkins L, Piña IL Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019; 44:(5)148-172 https://doi.org/10.1016/j.cpcardiol.2018.11.002

Criado Perez C Invisible women: exposing data bias in a world designed for men.: Vintage; 2019

European AIDS Treatment Group. Why people living with HIV must be included in non-HIV clinical trials. 2022. https://tinyurl.com/35xvxy5h (accessed 25 February 2025)

European AIDS Treatment Group. What we wanted was what we needed: a model of inclusive community advocacy. 2023a. https://tinyurl.com/55zeayza (accessed 25 February 2025)

European AIDS Treatment Group. Belong – Inclusion of people living with HIV in non-HIV clinical trials. 2023b. https://tinyurl.com/4vbcbzxx (accessed 25 February 2025)

European AIDS Treatment Group. Reporting from Living 2024 Community Workshop: ‘Why people living with HIV must be included in non-HIV clinical trials’. 2024. https://tinyurl.com/4ypsft5k (accessed 25 February 2025)

Fairlie L, Waitt C, Lockman S Inclusion of pregnant women in antiretroviral drug research. J Int AIDS Soc. 2019; 22:(9) https://doi.org/10.1002/jia2.25372

Health Research Authority. Help shape our new inclusion and diversity guidance. 2024. https://tinyurl.com/yc6patcf (accessed November 2024)

Iyizoba-Ebozue Z, Fatimilehin A, Mbanu P, Adeleke S Reflection on black and ethnic minority participation in clinical trials. Clin Oncol (R Coll Radiol). 2022; 34:(10)674-677 https://doi.org/10.1016/j.clon.2022.07.006

Johnston CD, O'Brien R, Côté HCF Inclusion of women in HIV research and clinical trials. AIDS. 2023; 37:(6)995-997 https://doi.org/10.1097/QAD.0000000000003514

Morales DR, Moreno-Martos D, Matin N, McGettigan P Health conditions in adults with HIV compared with the general population: a population-based cross-sectional analysis. EClinicalMedicine. 2022; 47 https://doi.org/10.1016/j.eclinm.2022

Reuss JE, Stern D, Foster JC Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-PD1/PDL1 clinical trials. JAMA Netw Open. 2020; 3:(12) https://doi.org/10.1001/jamanetworkopen

World Health Organization. Approaches to enhance and accelerate study of new drugs for HIV and associated infections in pregnant women. 2021. https://tinyurl.com/j7zzhwtf (accessed 25 February 2025)

Including people with HIV in non-HIV clinical trials

06 March 2025
Volume 34 · Issue 5
Elderly person with HIV

Abstract

As HIV has transitioned from an acute to a chronic, managed condition, the quality of life and life expectancy of people living with HIV have both improved significantly. The new health challenges for people living and ageing with HIV are the prevention and treatment of non-HIV conditions. But what information do we have about how treatments for non-HIV conditions may impact on a person living with HIV and their antiretroviral (ARV) medication?

 

As HIV has transitioned from an acute to a chronic, managed condition, the quality of life and life expectancy of people living with HIV have both improved significantly. The new health challenges for people living and ageing with HIV are the prevention and treatment of non-HIV conditions. But what information do we have about how treatments for non-HIV conditions may impact on a person living with HIV and their antiretroviral (ARV) medication?

Data gaps in pharmacological data are not unusual. The need for clinical trials to gather ‘clean’ data and guarantee commercial gain often leads to the exclusion of ‘complicating factors’, such as participants with pre-existing conditions or other groups such as women of child-bearing age or those perceived as ‘hard to reach’. The result is that medication-related data is skewed, for example, towards mainly white cisgender males (Criado Perez, 2019).

The lack of Black and ethnic minority groups included in clinical trials has been highlighted in cancer care (Iyizoba-Ebozue et al, 2022) and cardiology (Clark et al, 2019). Recently, there have been attempts to include more diversity in clinical trials. The UK's Health Research Authority (2024) has been working in collaboration with the Medicines and Health products Regulatory Agency to produce guidelines that ensure research includes people who could be impacted by the findings.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content